Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.58 |
| ▸ | MME | P08473 | 5/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 3/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22503673 | 0.88 | MME (0.59) | ACEMMEACE2ALDH1A1NPSR1 | |
| SCHEMBL30000054 | 0.88 | ACE (0.56) | ACEMMEACE2ALDH1A1NPSR1 | |
| SCHEMBL8726475 | 0.86 | ACE (0.63) | ACEMMEACE2ALDH1A1NPSR1 | |
| SCHEMBL30587429 | 0.86 | ACE (0.59) | ACEMMEACE2NPSR1CPA1 | |
| SCHEMBL908204 | 0.86 | ACE (0.63) | ACEMMEACE2ALDH1A1NPSR1 | |
| SCHEMBL2550703 | 0.86 | FOLH1 (0.61) | ACEMMEACE2NPSR1CA2 | |
| SCHEMBL2550705 | 0.86 | FOLH1 (0.61) | ACEMMEACE2NPSR1CA2 | |
| SCHEMBL908205 | 0.86 | ACE (0.63) | ACEMMEACE2ALDH1A1NPSR1 | |
| SCHEMBL12863002 | 0.86 | NPSR1 (0.69) | ACEMMEACE2NPSR1CPA1 | |
| SCHEMBL17468460 | 0.86 | NPSR1 (0.69) | ACEMMEACE2NPSR1CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115340468-B | (R) -deuterated phenylalanine derivative and preparation method thereof | 西南大学 | 2023-10-24 | — | — | CN | disclosed |
| CN-115340468-A | (R) -deuterated phenylalanine derivative and preparation method thereof | 西南大学 | 2022-11-15 | — | — | CN | disclosed |
| EP-0873320-B1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| US-6087357-A | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | PKD2, SSTR5, TAC3 | ACE 488/4885MME 589/4885ACE2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.